Russell Investments Group Ltd. bought a new stake in Jounce Therapeutics Inc (NASDAQ:JNCE) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 32,224 shares of the company’s stock, valued at approximately $502,000. Russell Investments Group Ltd. owned 0.10% of Jounce Therapeutics as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the business. Redmile Group LLC boosted its stake in Jounce Therapeutics by 2.2% in the second quarter. Redmile Group LLC now owns 1,138,370 shares of the company’s stock valued at $15,971,000 after acquiring an additional 24,210 shares during the period. Vanguard Group Inc. boosted its stake in Jounce Therapeutics by 123.8% in the second quarter. Vanguard Group Inc. now owns 255,060 shares of the company’s stock valued at $3,578,000 after acquiring an additional 141,096 shares during the period. Conning Inc. boosted its stake in Jounce Therapeutics by 36.0% in the third quarter. Conning Inc. now owns 125,960 shares of the company’s stock valued at $1,962,000 after acquiring an additional 33,350 shares during the period. State Street Corp boosted its stake in Jounce Therapeutics by 120.6% in the second quarter. State Street Corp now owns 100,233 shares of the company’s stock valued at $1,409,000 after acquiring an additional 54,803 shares during the period. Finally, Fosun International Ltd acquired a new position in Jounce Therapeutics in the second quarter valued at approximately $1,456,000. Institutional investors own 47.51% of the company’s stock.
Several equities analysts have recently issued reports on JNCE shares. Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, January 3rd. JPMorgan Chase & Co. set a $28.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, Robert W. Baird reiterated a “buy” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a research report on Friday, November 10th. Five equities research analysts have rated the stock with a buy rating, Jounce Therapeutics has a consensus rating of “Buy” and an average target price of $24.00.
Jounce Therapeutics Inc (NASDAQ:JNCE) opened at $15.37 on Friday. The stock has a market capitalization of $495.62 and a P/E ratio of -90.41. Jounce Therapeutics Inc has a 52-week low of $11.05 and a 52-week high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.12. The business had revenue of $18.10 million during the quarter, compared to the consensus estimate of $20.00 million. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. Jounce Therapeutics’s quarterly revenue was up 7.1% on a year-over-year basis. research analysts expect that Jounce Therapeutics Inc will post -0.86 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Russell Investments Group Ltd. Invests $502,000 in Jounce Therapeutics Inc (JNCE) Stock” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/russell-investments-group-ltd-acquires-shares-of-32224-jounce-therapeutics-inc-jnce.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.